For decades, self-funding and alternative health plan models lived in the domain of Fortune 500 enterprises—organizations with thousands of employees, sophisticated finance teams, and the risk tolerance to absorb catastrophic claims. The middle market watched from the sidelines, locked into fully-insured arrangements that offered predictability at the cost of transparency, control, and upside. But something fundamental has shifted. Cost containment has officially overtaken talent attraction as employers’ #1 strategic priority for 2026, and 36% of employers are now actively considering alternative health plan models—up dramatically from the 24% currently offering them. The mid-market migration has begun, and it’s accelerating faster than most brokers anticipated.

This isn’t speculative trend-watching. A December 2025 survey of 1,241 employers reveals that 60% expect to evaluate level-funded, self-insured, reference-based pricing, or direct contracting arrangements by 2028. That’s not a marginal shift—it’s a wholesale recalibration of how middle-market organizations think about health benefits financing. And the pressure driving it is unmistakable: small group fully-insured premiums rose a median 11% for 2026 renewals, GLP-1 pharmacy costs are rewriting budget models, and employers are finally demanding visibility into where their healthcare dollars actually go. For HR Directors at organizations with 100 to 5,000 employees, the question is no longer “Should we consider alternatives?” but “How do we evaluate them without getting burned?”

The Fully-Insured Model Is Breaking Down—and Employers Know It

Fully-insured health plans offer one compelling advantage: predictability. You pay a premium, the carrier assumes the risk, and your budget exposure is capped. For many organizations, that certainty justified premium pricing, limited transparency, and zero control over claims management, pharmacy strategy, or network design. But that value proposition is eroding under the weight of three converging forces.

First, premium increases have become structurally unsustainable. Median 11% increases for small group plans in 2026 aren’t anomalies—they’re the new baseline. And unlike past cycles where increases moderated after a few tough years, the drivers this time are persistent: an aging population, specialty drug costs doubling every five years, utilization returning post-pandemic, and carriers rebuilding margins after ACA risk-adjustment losses. Employers are staring at compounding 8-12% annual increases with no end in sight.

Second, transparency has become a competitive imperative. Fully-insured models operate as black boxes. Employers don’t see claims data, can’t audit pharmacy rebates, and have no insight into network performance or utilization patterns. That opacity was tolerable when premiums felt reasonable. But when you’re writing checks for $2 million annually in health benefits, not knowing whether your carrier retained 15% or 25% as margin feels like malpractice. Self-funded and level-funded arrangements flip that dynamic—complete claims visibility, transparent administrative fees, and direct control over vendor relationships.

Third, alternatives have become operationally accessible. Ten years ago, self-funding required building internal expertise, managing cash flow volatility, and navigating complex stop-loss markets without experienced guidance. Today, level-funded arrangements offer self-funding economics with fully-insured simplicity: fixed monthly payments, carrier-administered claims, and minimal cash flow risk. Technology platforms provide real-time claims dashboards, predictive analytics, and pharmacy optimization tools that were enterprise-only five years ago. The operational barriers that kept mid-market employers in fully-insured plans have largely disappeared.

What “Alternative” Actually Means: A Taxonomy of Options

The language around alternative funding models is confusing, often deliberately so. Brokers use terms like “level-funded,” “self-insured,” “captive,” and “reference-based pricing” interchangeably, creating the impression these are variations on a theme rather than distinct strategies with different risk profiles, cost structures, and implementation requirements. Let’s clarify what we’re actually talking about.

Level-Funded Plans: This is the entry point for most mid-market employers. You pay a fixed monthly amount—just like fully-insured—but the structure underneath is self-funded. Your monthly payment covers projected claims, stop-loss premiums, and administrative fees. If actual claims come in below projections, you receive a refund at year-end. If they exceed projections but stay within your stop-loss corridor, you absorb the variance. Level-funding eliminates cash flow volatility while providing claims transparency and upside capture. It’s ideal for organizations with 50-500 employees testing the waters of self-funding without operational disruption.

Traditional Self-Funding: This is full risk assumption with stop-loss protection. You pay claims as they’re incurred, contract directly with a TPA for administration, purchase stop-loss insurance to cap catastrophic exposure, and retain all underwriting margin. Monthly costs fluctuate with utilization, requiring robust cash reserves or a line of credit. But the control is absolute—you choose the TPA, design the pharmacy strategy, negotiate directly with vendors, and capture 100% of favorable claims experience. Organizations with 250+ employees and financial discipline tend to thrive here.

Captive Arrangements: Group captives pool risk across multiple employers, creating economies of scale while preserving self-funded advantages. You share underwriting results with other captive members, spreading catastrophic claim risk more broadly than individual stop-loss alone. Captives often outperform commercial carriers by 15-20 percentage points on combined ratio because they eliminate carrier profit margins and operate with aligned incentives. For mid-market employers, joining an established captive offers sophisticated risk management without building internal infrastructure. Atria has been particularly aggressive in bringing captive solutions to tribal nations, where pooling sovereign employers creates unique advantages around network negotiation and regulatory alignment.

Reference-Based Pricing (RBP): This is the most disruptive model, and the riskiest. Instead of contracting with PPO networks at pre-negotiated rates, RBP plans pay providers based on a reference point—typically Medicare rates plus a percentage (e.g., Medicare + 140%). This can generate 20-40% savings on facility costs, but it shifts balance billing risk to employees and creates provider relation challenges. RBP works best paired with strong employee advocacy and in markets with provider competition. It’s not for every employer, but for those willing to invest in communication and advocacy infrastructure, the savings can be transformational.

Direct Contracting and Centers of Excellence: Rather than relying on carrier networks, some employers contract directly with providers for high-cost services—joint replacements, cardiac procedures, cancer care, transplants. These arrangements bundle quality, outcomes, and cost into a single negotiated rate, often including travel and lodging for the patient. The savings range from 30-50% compared to PPO network rates, with better outcomes. This isn’t theoretical—it’s what companies like Walmart, Boeing, and Lowe’s have been doing for years. Now, coalitions are bringing the same model to employers with as few as 500 employees.

The Stop-Loss Market: Your Safety Net—If You Understand It

Self-funding without competent stop-loss underwriting is financial recklessness. The stop-loss market is projected to grow from $27 billion today to $113 billion by 2034—proof that alternative funding is moving mainstream. But stop-loss is also where employers without sophisticated advisors get exploited. The terminology alone is designed to confuse: specific deductibles, aggregate corridors, lasering, contract year vs. plan year, run-in/run-out provisions, advance funding obligations. Most HR Directors encounter this vocabulary for the first time while being asked to make multimillion-dollar risk decisions.

Here’s what matters. Your specific deductible determines when stop-loss coverage kicks in for individual catastrophic claims—typically $100K to $250K depending on group size. If an employee incurs a $500K claim and your specific deductible is $150K, you pay the first $150K and stop-loss covers the remaining $350K. But the details determine whether that protection is real or illusory. Does your contract include 12/12 coverage (claims incurred and paid within the contract period) or 12/15, 15/12, or other variations that shift risk? Are there laser provisions allowing the carrier to increase your specific deductible on known high-cost claimants? What are the advance funding requirements if you have active large claims at renewal?

Aggregate stop-loss protects against the accumulation of many smaller claims exceeding your budgeted corridor. If you budget for $1.2M in annual claims but actual claims reach $1.5M, aggregate coverage reimburses the $300K difference—assuming you’ve structured your corridor properly. But aggregate is where employers frequently underinsure. A 120% corridor sounds conservative until you realize it means absorbing 20% variance before protection activates. In a $1.5M budget scenario, that’s $300K of unplanned exposure.

The sophistication required to navigate this isn’t something most brokers possess. Large national firms often default to carrier recommendations without challenging attachment points, corridor widths, or contract terms. At Atria, we treat stop-loss procurement as a negotiation—not order-taking. That means modeling multiple scenarios, stress-testing your risk tolerance, benchmarking deductibles against peer groups, and demanding transparency on carrier reserves and rate development. Stop-loss should protect you. But only if your advisor knows how to buy it properly.

The PBM Reckoning: Why 41% of Employers Are Changing Direction

Pharmacy spend represents 20-25% of total health plan costs—and it’s where alternative funding models create immediate leverage. Under fully-insured arrangements, your PBM relationship is bundled into the carrier contract. You have no visibility into rebate retention, spread pricing, or formulary decisions. The carrier negotiates with the PBM, keeps an undisclosed portion of savings, and you’re left hoping their interests align with yours. Spoiler: they don’t.

Self-funding changes everything. You contract directly with the PBM or carve out pharmacy entirely. That visibility has driven 41% of employers to either switch PBMs or launch RFPs, with 27% specifically moving toward transparent, pass-through PBM models. These arrangements eliminate spread pricing—where PBMs charge you more than they pay pharmacies and pocket the difference—and return 100% of manufacturer rebates to you rather than retaining them as profit.

For context, traditional PBM contracts retain 15-30% of rebate value. On a $500K annual pharmacy spend, that’s $75K-$150K in margin you’re surrendering. Transparent PBM models charge an administrative fee (typically $3-$8 per member per month) and return everything else. The math is straightforward, but execution requires expertise. You need advisors who understand DIR fees, MAC pricing, therapeutic interchange protocols, and specialty drug sourcing strategies. This is where large brokers falter—they lack the technical depth to negotiate effectively, defaulting instead to incumbent PBM relationships that preserve their own revenue streams.

Who Should Move—and Who Shouldn’t (Yet)

Not every employer is ready for alternative funding. Organizations with fewer than 50 employees often lack the risk pool to absorb volatility. Groups with unstable headcount—rapid growth, seasonal hiring, or high turnover—struggle with the underwriting discipline self-funding requires. And employers without financial reserves to weather adverse claims experience should stay fully-insured until their balance sheet strengthens.

But the threshold is lower than most think. Level-funded plans work effectively for groups as small as 50 employees. Traditional self-funding becomes viable at 250 employees if leadership has risk tolerance and cash reserves. By 400 employees, staying fully-insured without at least evaluating alternatives borders on fiduciary negligence—you’re almost certainly overpaying by 10-20% annually.

What Your Broker Should Be Doing (But Probably Isn’t)

The difference between a successful transition to alternative funding and a financial disaster often comes down to broker competence. This is not a space for generalists. You need advisors who live in self-funded markets, understand actuarial modeling, negotiate stop-loss daily, and can translate complex risk concepts into executive-level decision frameworks.

Here’s the minimum your broker should deliver if you’re evaluating alternatives:

Actuarial Analysis: Not generic benchmarking—actual modeling of your claims history, demographic risk factors, and utilization trends to project expected costs under self-funded arrangements with multiple stop-loss scenarios.

Stop-Loss Market Intelligence: Quotes from at least three carriers, comparison of contract terms (not just pricing), and transparent recommendations on specific vs. aggregate balance based on your risk tolerance and financial capacity.

TPA Evaluation Framework: If you’re moving to traditional self-funding, TPA selection is mission-critical. Your broker should present options with detailed service level agreements, claims payment accuracy metrics, reporting capabilities, and references from similar-sized employers.

Pharmacy Strategy: Whether that’s transparent PBM sourcing, specialty drug carve-outs, direct manufacturer contracting, or clinical management programs—your broker should have concrete recommendations backed by data, not vendor relationships.

Multi-Year Financial Modeling: Alternative funding is a three-to-five-year strategy. Your broker should project costs, cash flow, and risk exposure across that timeline—not just focus on year-one savings.

If your broker can’t deliver this, you’re working with the wrong firm. Large national brokers often lack the technical depth or the incentive structure—they’re compensated based on premium volume, which fully-insured plans maximize. Atria operates differently. We’re compensated for outcomes, not transactions, which means our incentives align completely with cost control and long-term value.

The 2026 Imperative: Why Waiting Gets More Expensive

Timing matters here more than employers realize. Fully-insured premium increases compound—11% this year becomes 12% next year on an already-elevated base. The longer you wait, the wider the gap between what you’re paying and what you should be paying. Meanwhile, stop-loss markets tighten when claims inflation accelerates, making entry more expensive.

Organizations evaluating alternatives in early 2026 have an advantage. Stop-loss carriers are still pricing competitively, TPA capacity exists, and you have time to implement thoughtfully rather than rushing a mid-year transition. By 2027, with McKinsey projecting 12 million additional employees shifting to self-funded models, that capacity will tighten and pricing will reflect increased demand.

Bottom Line

The mid-market migration to alternative health plan models isn’t a future trend—it’s happening now. Cost pressures, transparency demands, and operational accessibility have converged to make self-funding, level-funding, and captive arrangements viable for organizations that were locked into fully-insured plans just five years ago. But navigating this transition successfully requires technical expertise, actuarial discipline, and strategic advising that goes far beyond traditional brokerage. Employers that move thoughtfully, with competent guidance, will capture 10-20% cost savings while gaining control over their largest benefit expense. Those that stay fully-insured by default—or worse, transition poorly with inadequate support—will watch costs spiral while competitors build sustainable advantages. At Atria, we don’t just explain alternatives. We build them, negotiate them, and stand behind them with the technical depth and long-term partnership middle-market employers deserve.

This article is for informational purposes only and should not be considered legal or tax advice.